pravastatin has been researched along with Myocardial Infarction in 255 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 63 (24.71) | 18.2507 |
| 2000's | 150 (58.82) | 29.6817 |
| 2010's | 40 (15.69) | 24.3611 |
| 2020's | 2 (0.78) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Hu, L; Jia, J; Liu, X; Luo, X; Ou, Y; Shen, W; Shi, H; Sun, S; Zhang, H; Zhou, G | 1 |
| Hoang, T; Kim, J | 1 |
| Colquhoun, DM; Glozier, N; Kirby, AC; Marschner, SL; Nestel, PJ; O'Neil, A; Oldenburg, B; Simes, J; Stewart, RAH; Tonkin, AM; White, HD | 1 |
| Ahn, CM; Cheong, SS; Cho, DK; Cho, YH; Choi, D; Her, AY; Hong, MK; Im, E; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Lee, K; Shin, DH; Suh, Y; Yoo, SY; Yun, KH | 1 |
| Chen, J; Li, H; Li, N; Liu, C; Sun, J; Wang, C | 1 |
| Beck, B; Donner, D; du Toit, EF; Headrick, JP; Oi, M; Peart, J; Wendt, L | 1 |
| Chertow, GM; Erickson, KF; Garber, AM; Goldhaber-Fiebert, JD; Japa, S; Owens, DK | 1 |
| Jha, V; Modi, GK | 1 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Morino, Y; Nozue, T; Onishi, Y; Sozu, T; Takeyama, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Cobbe, SM; Ford, I; Marchbank, L; McConnachie, A; Packard, CJ; Peacock, J; Robertson, M; Walker, A | 1 |
| Kang, S; Liu, XB; Liu, Y | 1 |
| Barnes, EH; Blankenberg, S; Colquhoun, DM; Fournier, M; Nestel, PJ; Simes, J; Sullivan, DR; Tonkin, AM; White, HD | 1 |
| Blankenberg, S; Colquhoun, D; Hunt, D; Keech, AC; Mann, K; Nestel, P; Simes, J; Stewart, R; Sullivan, D; Thompson, P; Tonkin, A; West, M; White, HD | 1 |
| Barnes, EH; Blankenberg, S; Colquhoun, DM; Hunt, D; Keech, AC; Marschner, IC; Nestel, P; Simes, J; Stewart, RA; Sullivan, DR; Thompson, P; Tonkin, A; West, M; White, HD; Zeller, T | 1 |
| Omland, T | 1 |
| Akao, H; Buckley, BM; de Craen, AJ; Ford, I; Jukema, JW; Kajinami, K; Packard, C; Polisecki, E; Robertson, M; Schaefer, EJ; Trompet, S | 1 |
| Ebisawa, S; Ikeda, U; Izawa, A; Kagoshima, M; Kashima, Y; Kitabayashi, H; Koyama, J; Miura, T; Miyashita, Y; Sakurai, S; Tomita, T; Yamamoto, H | 1 |
| Dohi, T | 1 |
| Cannon, CP; Khera, AV; Murphy, SA; Qamar, A; Rader, DJ; Sabatine, MS | 1 |
| Gandhi, HP; Patel, SS; Rathod, SP; Trivedi, JI; Variya, BC | 1 |
| El-Desouky, KI; El-Mahdy, N; El-Sayad, M; Salem, ML; Zaghow, N | 1 |
| Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD | 1 |
| Elsais, A; Kerty, E; Lund, C | 1 |
| Cui, J; Forbes, A; Kirby, A; Marschner, I; Simes, J; Tonkin, A; West, M | 1 |
| Blauw, GJ; Buckley, BM; de Craen, AJ; Ford, I; Forouhi, NG; Freeman, DJ; Jukema, JW; Macfarlane, PW; Murphy, MB; Murray, HM; Packard, CJ; Sattar, N; Shepherd, J; Stott, DJ; Welsh, P; Westendorp, RG | 1 |
| Barnes, EH; Colquhoun, D; Keech, A; Nestel, P; Pollicino, C; Simes, J; Söderberg, S; Tonkin, AM; Yallop, J | 1 |
| Blauw, GJ; Buckley, BM; Cobbe, S; de Craen, AJ; Ford, I; Jukema, JW; Lowe, GD; Macfarlane, PW; Murphy, MB; Murray, HM; Packard, CJ; Sattar, N; Shepherd, J; Stott, DJ; Welsh, P; Westendorp, RG | 1 |
| Aizawa, K; Ikeda, U; Izawa, A; Kasai, H; Kashima, Y; Koshikawa, M; Koyama, J; Kumazaki, S; Tomita, T; Tsutsui, H | 1 |
| Hennekens, C | 1 |
| Crow, RS; Davis, BR; Einhorn, PT; Ford, CE; Haywood, LJ; Massie, BM; Williard, A | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Ezaki, K; Hara, M; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Thuc, LC; Yufu, K | 1 |
| Acharjee, S; Cannon, CP; McCabe, C; Murphy, SA; Qin, J | 1 |
| Cui, J; Forbes, A; Hunt, D; Kirby, A; Marschner, I; Simes, J; Tonkin, A; West, M | 1 |
| Campos, H; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Louie, JZ; Sabatine, MS; Sacks, FM; Shiffman, D | 1 |
| Chen, CC; Hsu, YJ; Lee, TM; Lien, HY; Lin, CC; Shih, CM | 1 |
| D'Amico, M; Di Filippo, C; Monopoli, A; Ongini, E; Perretti, M | 1 |
| Bangalore, S; Cannon, CP; Murphy, SA; Qin, J; Sloan, S | 1 |
| Fefer, P; Hod, H; Matetzky, S; Novikov, I; Savion, N; Shechter, M; Shenkman, B; Varon, D | 1 |
| Caretta, G; Dei Cas, L; Della Pina, P; Gorga, E; Madureri, A; Raddino, R | 1 |
| Atar, I; Aydınalp, A; Bozbaş, H; Konaş, D; Korkmaz, ME; Mermer, S; Müderrisoğlu, H; Ozin, B; Yıldırır, A | 1 |
| Armani, A; Cannon, CP; McCabe, CH; Murphy, SA; Truong, QA | 1 |
| Braunwald, E; Pfeffer, MA; Ridker, PM; Sacks, FM | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| Heijmans, BT; Jukema, JW; Kremer, D; Lumey, LH; Putter, H; Sattar, N; Slagboom, PE; Talens, RP; Trompet, S; Westendorp, RG | 1 |
| Anastasiou-Nana, M; Andreadou, I; Farmakis, D; Iliodromitis, EK; Kremastinos, DT; Papalois, A; Papapetropoulos, A; Prokovas, E; Sigala, F; Spyridaki, K; Zoga, A | 1 |
| Brindisi, MC; Cottin, Y; Davani, S; Gambert, P; Gambert-Nicot, S; Kantelip, JP; Lorgis, L; Meneveau, N; Salvary, T; Schiele, F; Séronde, MF; Zeller, M | 1 |
| Bonaca, MP; Bui, AH; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS | 1 |
| Afonso, L; Arora, N; Bhattacharya, P; Ference, BA; Madhavan, R; Mahajan, N; Sacks, F; Sagar, A; Sudhakar, R; Wang, Y | 1 |
| Bang, CN; Gislason, GH; Greve, AM; Køber, L; Torp-Pedersen, C; Wachtell, K | 1 |
| Cannon, CP; Gibson, CM; Murphy, SA; Nazer, B; Ray, KK | 1 |
| Hara, M; Hori, M; Komuro, I; Matsumoto, S; Matsumura, Y; Minamino, T; Mizuno, H; Nakatani, D; Nishino, M; Okuda, K; Ozaki, K; Sakata, Y; Sato, H; Shimizu, M; Suna, S; Takashima, S; Takeda, H; Tanaka, T; Usami, M | 1 |
| Can, L; Kayikçioğlu, M; Kültürsay, H; Payzin, S; Turkoğlu, C | 1 |
| Saito, Y; Sasaki, N; Shinomiya, M; Shirai, K; Yoshida, S | 1 |
| Farmer, JA; Gotto, AM | 1 |
| Ahn, C; Aronow, WS | 1 |
| Bybee, KA; Kopecky, SL; LaBlanche, JM; Murphy, JG; Wright, RS | 1 |
| Gaw, A; Shepherd, J | 1 |
| März, W | 1 |
| Campos, H; Lee, SJ; Moye, LA; Sacks, FM | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Kerensky, RA; Monroe, VS; Pepine, CJ; Rivera, E; Smith, KM | 1 |
| Cole, T; Curhan, GC; Moyé, L; Sacks, FM; Tonelli, M | 1 |
| Arakawa, K; Iwashita, M; Kono, S; Matsushita, Y; Sasaki, J | 1 |
| Can, L; Evrengul, H; Kayikcioglu, M; Kultursay, H; Payzin, S | 1 |
| Baiano, A; de Cristofaro, A; Del Forno, D; Giallauria, F; Paragliola, T; Rossi, M; Vigorito, C | 1 |
| Arulchelvam, M; Baker, J; Beller, E; Best, J; Colquhoun, D; Hague, W; Hunt, D; Keech, A; Kirby, A; Simes, RJ; Tonkin, A | 1 |
| Origasa, H; Yokoyama, M | 1 |
| Brown, WV; Moussa, M | 1 |
| Chou, TF; Lee, TM; Tsai, CH | 1 |
| Furuta, H; Hayashi, T; Ishikawa, K; Kanamasa, K; Katayama, K; Kimura, A; Miyataka, M; Takenaka, T; Taniguchi, M; Yamamoto, T | 1 |
| Cannon, CP | 1 |
| Belder, R; Braunwald, E; Cannon, CP; Hill, KA; Joyal, SV; McCabe, CH; Pfeffer, MA; Rader, DJ; Rouleau, JL; Skene, AM | 1 |
| Topol, EJ | 1 |
| Agema, WR; Boer, JM; de Maat, MP; Feskens, EJ; Jukema, JW; Kastelein, JJ; Rabelink, TJ; van Boven, AJ; van der Wall, EE; Zwinderman, AH | 1 |
| Ehrenborg, E; Karpe, F; Ledmyr, H; Lithell, H; MacFarlane, PW; McMahon, AD; Neville, M; Nielsen, LB; Packard, CJ | 1 |
| Ahmed, M; Griffiths, P | 1 |
| Ford, I; Lowe, GD; McMahon, AD; O'Reilly, DS; Packard, CJ; Rumley, A | 1 |
| Amerena, J; Campbell, TJ; Harris, PJ; Meredith, I; Sloman, JG; Thompson, PL | 1 |
| Einecke, D | 1 |
| Li, J; Peng, DQ; Xu, ZM; Zhao, SP; Zhou, HN | 1 |
| van der Harst, P; van Veldhuisen, DJ; Voors, AA | 1 |
| LeLorier, J; Paradis, JM | 1 |
| Gotto, AM | 1 |
| Miller, M | 1 |
| Auer, J; Eber, B; Weber, T | 1 |
| Levenson, D | 1 |
| Baurand, A; Bergmann, MW; Dietz, R; El Jamali, A; Freund, C; Rechner, C | 1 |
| Cobbe, SM; Craven, T; Curhan, GC; Furberg, C; Isles, C; Pfeffer, MA; Sacks, FM; Shepherd, J; Simes, J; Tonelli, M; Tonkin, A; West, M | 1 |
| von Schacky, C | 1 |
| Asano, Y; Asanuma, H; Fujita, M; Hirata, A; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Minamino, T; Mori, H; Node, K; Ogai, A; Okuda, H; Sanada, S; Shinozaki, Y; Takashima, S; Tomoike, H | 1 |
| Carnero, A; Cubero, T; Giménez, DM; Gómez, AE; Gonzálvez, M; Lozano, ML; Martínez-Corbalán, F; Pérez-Paredes, M; Ruiz Ros, JA; Vicente, V | 1 |
| Cannon, CP; Ray, KK | 2 |
| Macfarlane, PW; Norrie, J | 2 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, D; Pfeffer, MA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Crowe, T; Ganz, P; Magorien, RD; Nissen, SE; O'Shaughnessy, C; Orazem, J; Sasiela, WJ; Schoenhagen, P; Tsai, J; Tuzcu, EM | 1 |
| Isley, WL | 1 |
| Farmer, JA | 1 |
| Colquhoun, DM; Heritier, SR; Kirby, AC; Nestel, PJ; Simes, RJ; Stewart, RA; Tonkin, AM; West, MJ; White, HD | 1 |
| Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Gu, SM; Wei, M; Wu, YH; Wu, ZG; Zhang, YY | 1 |
| Curhan, G; Jhangri, GS; Pfeffer, M; Sacks, F; Tonelli, M | 1 |
| Abildstrom, SZ; Buch, P; Friberg, J; Gislason, GH; Gustafsson, I; Køber, L; Madsen, M; Rasmussen, JN; Rasmussen, S; Stender, S; Torp-Pedersen, C | 1 |
| Austin, PC; Mamdani, MM | 1 |
| Cameron, JD; Hope, SA; Meredith, IT; Plunkett, JC; Worthley, SG | 1 |
| Lee, JD; Mitsuke, Y; Nakano, A; Nakaya, R; Shimizu, H; Ueda, T; Uzui, H; Yamazaki, T | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Jackson, G; McCabe, CH; Ray, KK; Sacks, FM; Tonkin, AM | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Pfeffer, MA; Ray, KK; Wiviott, SD | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Gibson, CM; Kirtane, AJ; McCabe, CH; Morrow, DA; Ray, KK; Ridker, PM; Rifai, N; Skene, AM | 1 |
| Rouleau, J | 1 |
| Ahumada, M; Arcas, R; Arribas, JM; Gomez-Plana, J; Marín, F; Martínez, P; Oliver, C; Pascual, DA; Tornel, PL; Valdes, M | 1 |
| Clearfield, M | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS | 1 |
| Foody, JM; Galusha, D; Havranek, EP; Krumholz, HM; Masoudi, FA; Radford, MJ; Rathore, SS | 1 |
| Chang, NC; Chou, TF; Lee, TM; Lin, MS | 1 |
| Hamano, K; Ito, H; Kobayashi, T; Li, TS; Mikamo, A; Suzuki, R; Takahashi, M | 1 |
| Feng, J; Sellke, FW | 1 |
| Denton, M; Eckermann, S; Friedlander, D; Glasziou, P; Hunt, D; Kirby, A; Magnus, P; Mulray, S; Sallaberger, M; Simes, J; Tonkin, AM; White, H | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Mega, JL; Morrow, DA; Murphy, S; Ridker, PM | 1 |
| Serón, D | 1 |
| Braunwald, E; Giugliano, RP | 1 |
| Poli, A; Pujia, A | 1 |
| Abe, Y; Ikewaki, K; Izumi, T; Mochizuki, S; Nagai, M; Taniguchi, I; Urabe, A | 1 |
| Goto, Y; Kanda, M; Kinoshita, H; Miyazaki, S; Nagaya, N; Nonogi, H; Yasuda, S | 1 |
| Campos, H; Catanese, JJ; Chokkalingam, AP; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Leong, DU; Lew, D; Louie, JZ; Luke, MM; Packard, CJ; Ploughman, LM; Rowland, CM; Sabatine, MS; Sacks, FM; Shaw, PM; Shepherd, J; Tong, CH; Tsuchihashi, Z; Young, BA; Zerba, KE | 1 |
| Chang, NC; Lee, TM; Lin, MS; Tsai, CH | 1 |
| Cannon, CP; Ganz, P; Ray, KK | 1 |
| Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Klungel, OH; Leiendecker-Foster, C; Maitland-van der Zee, AH; Miller, MB | 1 |
| Barlera, S; Chiodini, BD; D'Orazio, A; Franzosi, MG; Lewis, CM; Marchioli, R; Mocarelli, P; Nicolis, E; Signorini, S; Tognoni, G | 1 |
| Bax, JJ; Davignon, J; Dunkelgrun, M; Feringa, HH; Hoeks, SE; Kastelein, JJ; Poldermans, D; Schouten, O; van Domburg, RT; Vidakovic, R; Welten, GM | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Chang, NC; Lee, TM; Lin, MS | 1 |
| Arai, M; Bao, N; Fujiwara, H; Fujiwara, T; Iwasa, M; Kawamura, I; Kobayashi, H; Minatoguchi, S; Misao, Y; Nishigaki, K; Sumi, S; Takemura, G; Yamaki, T; Yasuda, S | 1 |
| Fujioka, D; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Yano, T | 1 |
| Cobbe, SM; Ford, I; Macfarlane, PW; Murray, H; Packard, CJ; Shepherd, J | 1 |
| Charbonnel, B; Dormandy, J; Erdmann, E; Massi-Benedetti, M; Wilcox, R | 1 |
| Cannon, CP; Kumar, A | 1 |
| Braunwald, E; Buros, J; Cannon, CP; Croce, K; Gao, H; Healy, AM; Libby, P; McCabe, CH; Morrow, DA; Pradhan, AD; Sabatine, MS; Sakuma, M; Simon, DI; Wang, Y | 1 |
| Fukunami, M; Hirayama, A; Hori, M; Ito, H; Kijima, Y; Kinjo, K; Koretsune, Y; Lim, YJ; Mizuno, H; Nakatani, D; Nanto, S; Nishino, M; Sato, H; Shimizu, M | 1 |
| Arellano, AR; Braunwald, E; Campos, H; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Packard, CJ; Pfeffer, MA; Rowland, CM; Sabatine, MS; Sacks, FM; Shepherd, J; Shiffman, D; Tong, CH; White, TJ; Young, BA | 1 |
| Braunwald, E; Cannon, CP; Miller, M; Murphy, SA; Qin, J; Ray, KK | 1 |
| Bickel, C; Blankenberg, S; Kirby, AC; Lubos, E; Münzel, TF; Nestel, PJ; Pollicino, C; Schnabel, R; Simes, RJ; Sullivan, D; Tiret, L; Tonkin, AM; West, MJ; White, HD | 1 |
| Farmer, JA; Jones, PH | 1 |
| Cobbe, SM; Ford, I; Isles, CG; Lorimer, AR; MacFarlane, PW; McKillop, JH; Packard, CJ; Shepherd, J | 1 |
| Shepherd, J | 1 |
| Bond, MG; Byington, RP; Crouse, JR; Espeland, MA; Furberg, CD | 1 |
| Byington, RP; Furberg, CD; McGovern, ME; Park, JS; Pitt, B | 1 |
| Bruschke, AV; Byington, RP; Furberg, CD; Hoen, H; Jukema, JW; Mancini, GB; Pitt, B; Salonen, JT | 2 |
| Ellis, SG; Mancini, GB; McGovern, ME; Park, JS; Pitt, B; Rosman, HS | 1 |
| Berg, A; Brusis, OA; Hasper, E; Kesten, D; Safian, PA; Scherwitz, LW; Siegrist, J | 1 |
| Fawcett, JP; Menkes, DB | 1 |
| Byington, RP; Crouse, JR; Espeland, MA; Furberg, CD | 1 |
| Manns, MP; Schmidt, HH; Wagner, S | 1 |
| Davis, BR; Meyers, DG; Rouleau, JL; Sacks, FM; Wilt, TJ | 1 |
| Diosy, A | 1 |
| Ashraf, T; Crouse, J; Davidson, M; Furberg, CD; Hay, JW; Pitt, B; Radican, L; Wittels, E | 1 |
| Klose, G | 1 |
| Arnold, JM; Braunwald, E; Brown, L; Cole, TG; Davis, BR; Moye, LA; Pfeffer, MA; Rouleau, JL; Rutherford, JD; Sacks, FM; Warnica, JW; Wun, CC | 1 |
| Game, F | 1 |
| Pederson, JP; Weintraub, WS | 1 |
| Willerson, JT | 1 |
| Force, R; Lawless, C | 1 |
| Sprecher, DL | 1 |
| Ettinger, WH; Hazzard, WR | 1 |
| Auerbach, I; Behar, S; Motro, M | 1 |
| Blanckaert, N; Claeys, G; Kesteloot, H; Lesaffre, E | 1 |
| Bhatnagar, D | 1 |
| von Eyben, FE | 1 |
| Hexeberg, E; Hjermann, I; Holme, I; Otterstad, JE | 1 |
| Bönner, G | 1 |
| Donaldson, C; Glasziou, PP; Hall, J; Simes, RJ | 1 |
| Rosenthal, N; Schwartz, RS | 1 |
| Caro, J; Ford, I; Klittich, W; McGuire, A; McMurray, J; Norrie, J; Pettitt, D; Shepherd, J | 1 |
| Verheugt, FW | 1 |
| Kesäniemi, YA | 1 |
| Braunwald, E; Cole, TG; Davis, BR; Moyé, LA; Nash, DT; Pfeffer, MA; Rouleau, JL; Sacks, FM | 1 |
| Gamble, G; Hart, H; MacMahon, S; Scott, J; Sharpe, N; Simes, J; White, H | 1 |
| Braunwald, E; East, C; Glasser, S; Kell, S; Letterer, R; Lewis, SJ; Limacher, M; Mitchell, JS; Moye, LA; Pfeffer, MA; Rouleau, JL; Sacks, FM | 1 |
| Braunwald, E; Flaker, GC; Goldman, S; Moye, LA; Pfeffer, MA; Ridker, PM; Rifai, N; Sacks, FM | 1 |
| Braunwald, E; Davis, BR; Glasser, SP; Grant, J; Johnstone, DE; Kell, S; Lewis, SJ; Limacher, M; Mitchell, J; Moye, LA; Pfeffer, MA; Sacks, FM; Timmis, G | 1 |
| Braunwald, E; Cole, TG; Davis, BR; Goldberg, RB; Howard, BV; Howard, WJ; Mellies, MJ; Moyé, LA; Pfeffer, MA; Sacks, FM | 1 |
| Bombing, MT; Costa, A; Ferreira Filho, C; Ferreira, C; Luna Filho, B; Murad, N; Póvoa, R; Simões, M | 1 |
| Hingorani, AD; Vallance, P | 1 |
| Furberg, CD | 1 |
| Bernstein, V; Braunwald, E; Cuddy, TE; Davis, BR; Moyé, LA; Pfeffer, MA; Piller, LB; Plehn, JF; Rouleau, JL; Rutherford, J; Sacks, FM; Simpson, LM | 1 |
| Braunwald, E; East, C; Goldman, S; Moyé, LA; Nash, DT; Pfeffer, MA; Rouleau, JL; Rouleau, JR; Sacks, FM; Sussex, BA; Theroux, P; Vanden Belt, RJ | 1 |
| Bloom, JM | 2 |
| Mahé, I | 1 |
| Braunwald, E; Davis, BR; Flaker, GC; Moyé, LA; Pfeffer, MA; Rouleau, JL; Sacks, FM; Warnica, JW; Webel, RR | 1 |
| Braunwald, E; Pfeffer, MA; Ridker, PM; Rifai, N; Sacks, F | 1 |
| Pedersen, TR | 1 |
| Agrawal, R; Arntz, HR; Fischer, F; Linderer, T; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W | 1 |
| Arntz, HR | 1 |
| Feely, J | 1 |
| Asanuma, H; Hori, M; Kitakaze, M; Komamura, K; Kuzuya, T; Minamino, T; Sato, H; Takeda, H; Ueda, Y | 1 |
| Babu, BR; Belew, K; Cohen, JD; Donohue, T; Drury, JH; Finn, J; Flaker, G; Labovitz, A; Ostdiek, J | 1 |
| Bertel, O; Darioli, R; Gutzwiller, F; Mordasini, R; Szucs, TD | 1 |
| Arnheim, K | 1 |
| Cozma, LS; Ogunko, A; Rees, A | 1 |
| Ridker, PM | 1 |
| Avellone, G; Bono, M; De Simone, R; Di Garbo, V; Di Raimondo, D; Raneli, G | 1 |
| Berger, K; März, W; Schäfer, JR; Szucs, TD | 1 |
| Alaupovic, P; Braunwald, E; Cole, TG; Moye, LA; Pfeffer, MA; Sacks, FM; Stampfer, MJ; Sussex, B | 1 |
| Caslake, MJ; Cooney, J; Ford, I; Krishna, M; Lowe, GD; Macphee, CH; McMahon, AD; O'Reilly, DS; Packard, CJ; Rumley, A; Suckling, KE; Wilkinson, FE | 1 |
| Agrawal, R; Arntz, HR; Fischer, F; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W | 1 |
| Fruchter, O | 1 |
| Meilof, JF; Uitdehaag, BM | 1 |
| Colquhoun, D; Emberson, J; Hague, W; Hunt, D; Keech, A; Lane, G; MacMahon, S; Shaw, J; Simes, RJ; Thompson, PL; Tonkin, AM; White, HD | 1 |
| Bettencourt, J; Davis, BR; Ford, CE; Furberg, CD; Geraci, TS; Kimmel, B; Kingry, C; Lusk, C; Nwachuku, C; Parks, H; Piller, LB; Pressel, SL; Simpson, LM; Wright, JT | 1 |
| Anderson, GM; Jackevicius, CA; Leiter, L; Tu, JV | 1 |
| Athyros, VG; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Barzilay, JI; Basile, JN; Ciocon, JO; Davis, BR; Goff, DC; Jones, CL; Randall, OS; Sweeney, ME | 1 |
| Goldman, L; Kuntz, KM; Orav, EJ; Sacks, FM; Tsevat, J; Weinstein, MC | 1 |
| Guthrie, RM | 1 |
| Ferbert, A | 1 |
| Colquhoun, D; Friedlander, D; Glasziou, P; Harris, P; Marschner, IC; Simes, RJ; Singh, BB; Thompson, P; Tonkin, A; White, H | 1 |
| Den Hartog, FR; Rila, H; Schaafsma, HJ; Van Kalmthout, PM; Van Loenhout, TT; Verheugt, FW | 1 |
| Braunwald, E; Bray, PF; Cannon, CP; Goldschmidt-Clermont, P; Moyé, LA; Pfeffer, MA; Sacks, FM | 1 |
| Auer, J; Eber, B | 1 |
| Chau, J; Cheung, BM; Kumana, CR; Lau, CP; Lauder, IJ; McGhee, SM | 1 |
| Colquhoun, D; Hague, W; Hunt, D; Keech, A; Marschner, IC; Shaw, J; Simes, RJ; Stewart, RA; Sullivan, D; Thompson, P; Tonkin, A; White, H | 1 |
| Belder, R; Braunwald, E; Breen, J; Cannon, CP; McCabe, CH | 1 |
| Böhm, M; Hamm, CW; Heeschen, C; Laufs, U; Snapinn, S; White, HD | 1 |
| de Boer, A; Fishman, PA; Heckbert, SR; Klungel, OH; Leufkens, HG; Psaty, BM; Sullivan, SD; Veenstra, DL | 1 |
| Braunwald, E; Brown, LE; Cole, TG; Hamm, P; Hawkins, CM; Moye', L; Pfeffer, MA; Sacks, FM | 1 |
26 review(s) available for pravastatin and Myocardial Infarction
| Article | Year |
|---|---|
Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2020 |
Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.
Topics: Aged; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Drug Costs; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Failure, Chronic; Male; Markov Chains; Myocardial Infarction; Pravastatin; Primary Prevention; Quality-Adjusted Life Years; Rhabdomyolysis; Risk; Sex Factors; Stroke; United States | 2013 |
Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Registries; Saphenous Vein; Simvastatin; Treatment Outcome; Young Adult | 2013 |
[Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes].
Topics: Aspirin; Atherosclerosis; Coronary Disease; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2007 |
[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention | 2010 |
Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit.
Topics: Angina, Unstable; Anticholesteremic Agents; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic | 2002 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Coronary Artery Disease; Coronary Thrombosis; Disease Progression; Endothelium, Vascular; Enoxaparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Macrophages; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pravastatin; Randomized Controlled Trials as Topic; Secondary Prevention; Severity of Illness Index | 2003 |
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2003 |
The next step in cardiovascular protection.
Topics: Angina, Unstable; Anti-Bacterial Agents; Anticholesteremic Agents; Atorvastatin; Chlamydia Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention | 2003 |
Statins and secondary prevention of coronary heart disease.
Topics: Adult; Aged; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin; Survival Analysis; Treatment Outcome | 2004 |
Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Chronic Disease; Comorbidity; Coronary Disease; Creatinine; Databases, Factual; Double-Blind Method; Drug Evaluation; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Randomized Controlled Trials as Topic; Risk | 2004 |
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.
Topics: Acute Disease; Animals; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; T-Lymphocytes | 2004 |
Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
The year in non-ST-segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Clopidogrel; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Prognosis; Pyrroles; Risk Assessment; Stents; Syndrome; Thrombolytic Therapy; Ticlopidine | 2006 |
Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2006 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
Adjunctive interventions in myocardial infarction: the role of statin therapy.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Occlusion; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.
Topics: Age Factors; Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Sex Factors; Survival Analysis; Treatment Outcome | 1995 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic | 1996 |
Serum triglycerides and clinical benefit in lipid-lowering trials.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Statin trials and goals of cholesterol-lowering therapy after AMI.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Europe; Humans; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; United States | 1999 |
Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events.
Topics: Angina Pectoris; Anticholesteremic Agents; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Recurrence | 1999 |
[Stroke, cholesterol and statins--are there new data about stroke prevention?].
Topics: Anticholesteremic Agents; Blood Pressure; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Risk Factors; Stroke | 2001 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
111 trial(s) available for pravastatin and Myocardial Infarction
| Article | Year |
|---|---|
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pravastatin; Stroke; Treatment Outcome | 2018 |
C-reactive protein and future cardiovascular events in statin-treated patients with angina pectoris: the extended TRUTH study.
Topics: Aged; Angina Pectoris; C-Reactive Protein; Cardiovascular Diseases; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Japan; Male; Middle Aged; Myocardial Infarction; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Quinolines; Regression Analysis; Risk Factors; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Health Resources; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Primary Prevention; Quality-Adjusted Life Years; State Medicine; Stroke; Treatment Outcome | 2014 |
Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.
Topics: Aged; Angina, Unstable; Australia; Biomarkers; Coronary Disease; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Middle Aged; Myocardial Infarction; New Zealand; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Up-Regulation | 2013 |
Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic
Topics: Adult; Aged; Angina, Unstable; Biomarkers; C-Reactive Protein; Coronary Disease; Follow-Up Studies; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Pravastatin; Risk Assessment; Stroke; Troponin I | 2014 |
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Predictive Value of Tests; Time Factors | 2013 |
ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.
Topics: Aged; Alleles; ATP Binding Cassette Transporter 1; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Genotype; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Polymorphism, Single Nucleotide; Pravastatin; Proportional Hazards Models; Stroke | 2014 |
Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydrophobic and Hydrophilic Interactions; Hypercholesterolemia; Japan; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Patient Acceptance of Health Care; Pravastatin; Recurrence; Single-Blind Method; Solubility | 2015 |
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Leptin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Pyrroles; Recurrence; Resistin; Retrospective Studies; Risk Factors; Survival Rate; Thrombolytic Therapy; United States | 2015 |
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Parametric conditional frailty models for recurrent cardiovascular events in the lipid study.
Topics: Adult; Aged; Effect Modifier, Epidemiologic; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Statistical; Myocardial Infarction; Pravastatin; Predictive Value of Tests; Risk Factors; Secondary Prevention; Sex Factors; Survival Analysis | 2008 |
Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study.
Topics: Adiponectin; Aged; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Pravastatin; Recurrence; Risk; Stroke | 2009 |
Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Female; Fibrinogen; Humans; Inflammation; Interleukin-6; Kaplan-Meier Estimate; Male; Myocardial Infarction; Pravastatin; Risk Factors; Stroke | 2009 |
Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Prospective Studies; Pyrroles; Research Design | 2009 |
Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; Comorbidity; Doxazosin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Kaplan-Meier Estimate; Myocardial Infarction; Pravastatin; Prognosis; Smoking | 2009 |
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Regression Analysis; Secondary Prevention; Stroke | 2009 |
Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial.
Topics: Alleles; Atherosclerosis; Cholesterol; DNA; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genetic Predisposition to Disease; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Myocardial Infarction; Polymerase Chain Reaction; Polymorphism, Genetic; Pravastatin; Prevalence; Prospective Studies; Risk Factors; Secondary Prevention; Survival Rate; Treatment Outcome; United States | 2010 |
What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TI
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prognosis; Proportional Hazards Models; Pyrroles; Risk Factors; Thrombolytic Therapy; Treatment Outcome | 2010 |
Pravastatin therapy fails to suppress post-PCI inflammatory response measured by serum neopterin and CRP levels.
Topics: Adult; Aged; Aged, 80 and over; Angina, Stable; Angioplasty, Balloon, Coronary; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Neopterin; Pravastatin; Premedication; Stents; Vasculitis | 2011 |
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Sex Characteristics; Stroke; Treatment Outcome | 2011 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
Hypermethylation at loci sensitive to the prenatal environment is associated with increased incidence of myocardial infarction.
Topics: Aged; Aged, 80 and over; DNA Methylation; Epigenesis, Genetic; Female; Fetal Nutrition Disorders; Follow-Up Studies; Gene-Environment Interaction; Genetic Loci; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Myocardial Infarction; Pravastatin; Pregnancy; Prenatal Exposure Delayed Effects; Prospective Studies; Risk Factors | 2012 |
Pravastatin reverses the membrane cholesterol reorganization induced by myocardial infarction within lipid rafts in CD14(+)/CD16(-) circulating monocytes.
Topics: Adult; Anticholesteremic Agents; Caveolae; Caveolin 1; Cells, Cultured; Cholesterol; Female; Gene Expression Regulation; GPI-Linked Proteins; Humans; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Myocardial Infarction; Pravastatin; Receptors, IgG | 2012 |
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Placenta Growth Factor; Pravastatin; Pregnancy Proteins; Pyrroles; Risk Factors | 2012 |
Role of non-high-density lipoprotein cholesterol in predicting cerebrovascular events in patients following myocardial infarction.
Topics: Aged; Cerebrovascular Disorders; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Risk Factors; Triglycerides | 2012 |
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Anticholesteremic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors | 2013 |
Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cohort Studies; Combined Modality Therapy; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin | 2002 |
Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) Study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Anticholesteremic Agents; Arrhythmias, Cardiac; Cause of Death; Female; Follow-Up Studies; Heart Failure; Humans; Hypercholesterolemia; Incidence; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prognosis; Prospective Studies; Risk Factors | 2002 |
The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study.
Topics: Aged; Anticholesteremic Agents; Cost of Illness; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Patient Selection; Pravastatin; Research Design; Risk Factors; Scotland; Treatment Outcome | 2002 |
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.
Topics: Aged; Creatine Kinase; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proteinuria; Severity of Illness Index; Single-Blind Method | 2003 |
Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study.
Topics: Aged; Anticholesteremic Agents; Cerebral Infarction; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Risk; Treatment Outcome | 2003 |
The effect of statin therapy on ventricular late potentials in acute myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prospective Studies; Time Factors; Ventricular Dysfunction, Left | 2003 |
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Fasting; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors; Stroke; Treatment Outcome | 2003 |
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Chemotherapy, Adjuvant; Coronary Artery Disease; Death, Sudden, Cardiac; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prospective Studies; Simvastatin | 2003 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles | 2004 |
An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men.
Topics: Anticholesteremic Agents; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease Progression; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Pravastatin; Statistics, Nonparametric | 2004 |
The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease.
Topics: Abetalipoproteinemia; Anticholesteremic Agents; Biopsy; Carrier Proteins; Case-Control Studies; Cholesterol, LDL; Codon; Cohort Studies; Coronary Disease; Disease Susceptibility; Double-Blind Method; Genotype; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipoproteins; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Myocardium; Polymorphism, Genetic; Pravastatin; Promoter Regions, Genetic; Prospective Studies; Risk; RNA, Messenger; Scotland; Sweden | 2004 |
Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Case-Control Studies; Coronary Disease; Factor VII; Factor XIIa; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Incidence; Inflammation; Interleukin-6; Male; Middle Aged; Monocytes; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Predictive Value of Tests; Risk Factors; Scotland; Thrombophilia; Triglycerides | 2004 |
Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Cholesterol; Double-Blind Method; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Risk | 2004 |
Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction.
Topics: Anticholesteremic Agents; C-Reactive Protein; CD40 Ligand; Double-Blind Method; Female; Humans; Male; Matrix Metalloproteinase 9; Myocardial Infarction; Pravastatin | 2004 |
[Effect of the early administration of pravastatin on C-reactive protein and interleukin-6 levels in the acute phase of myocardial infarction with ST segment elevation].
Topics: Aged; Anticholesteremic Agents; C-Reactive Protein; Data Interpretation, Statistical; Female; Humans; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Pravastatin; Time Factors | 2004 |
Looking for prognostic information in the ST-T segment--is it really worth it?
Topics: Age Factors; Anticholesteremic Agents; Cause of Death; Cohort Studies; Double-Blind Method; Electrocardiography; Follow-Up Studies; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Myocardial Infarction; Placebos; Pravastatin; Predictive Value of Tests; Prognosis; Risk Assessment; Signal Processing, Computer-Assisted; Smoking | 2004 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Risk Factors; Secondary Prevention | 2005 |
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Regression Analysis; Risk Factors; Secondary Prevention; Ultrasonography, Interventional | 2005 |
White blood cell count predicts reduction in coronary heart disease mortality with pravastatin.
Topics: Aged; Biomarkers; Coronary Disease; Female; Humans; Inflammation; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Pravastatin; Predictive Value of Tests; Prognosis; Stroke; Survival Rate | 2005 |
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention; Statistics as Topic; Survival Rate; Treatment Outcome | 2005 |
Biomarkers of inflammation and progression of chronic kidney disease.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Disease Progression; Etanercept; Female; Humans; Hyperlipidemias; Immunoglobulin G; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Myocardial Infarction; Pravastatin; Receptors, Tumor Necrosis Factor | 2005 |
Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering.
Topics: Aged; Angina, Unstable; Biomarkers; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Logistic Models; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors | 2005 |
Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction.
Topics: Aged; Cholesterol, HDL; Female; Follow-Up Studies; Heart Ventricles; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 2; Middle Aged; Myocardial Infarction; Pravastatin; Stroke Volume; Time Factors; Tissue Inhibitor of Metalloproteinase-2; Treatment Outcome; Triglycerides; Vasodilation | 2005 |
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; Time Factors | 2005 |
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors; Syndrome | 2005 |
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Comorbidity; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Hospital Mortality; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Interleukin-6; Lipids; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Premedication; Preoperative Care; Prospective Studies; Pyrroles; Risk Assessment; Simvastatin; Systemic Inflammatory Response Syndrome; Troponin T | 2006 |
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Disease; Atorvastatin; Coronary Disease; Double-Blind Method; Enzymes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Pyrroles; Survival Analysis; Syndrome; Thrombolytic Therapy; Treatment Outcome | 2006 |
Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
Topics: Acute Disease; Adult; Age Factors; Aged; Angina, Unstable; Anticholesteremic Agents; Cost-Benefit Analysis; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Survival Rate; Syndrome | 2006 |
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Epidemiologic Methods; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Stroke | 2006 |
The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study.
Topics: Aged; Anticholesteremic Agents; Diagnosis, Computer-Assisted; Electrocardiography; Humans; Incidence; Longitudinal Studies; Male; Mass Screening; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Pravastatin; Primary Prevention; Prognosis; Proportional Hazards Models; Reproducibility of Results; Risk Assessment; Risk Factors; Scotland; Sensitivity and Specificity; Survival Analysis; Survival Rate; Treatment Outcome | 2007 |
Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study.
Topics: Apolipoproteins E; Female; Follow-Up Studies; Genotype; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Polymorphism, Genetic; Pravastatin; Treatment Outcome | 2007 |
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Long-term follow-up of the West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Pravastatin | 2007 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
Topics: Acute Coronary Syndrome; Aged; Anti-Infective Agents; Atorvastatin; Biomarkers; Calgranulin A; Calgranulin B; Case-Control Studies; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Probability; Pyrroles; Reference Values; Risk Assessment; Survival Rate; Thrombolytic Therapy; Treatment Outcome | 2008 |
Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study.
Topics: Aged; Angina, Unstable; Death; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Secondary Prevention; Stroke; Treatment Outcome | 2008 |
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Triglycerides | 2008 |
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Humans; Hypercholesterolemia; Incidence; Male; Middle Aged; Myocardial Infarction; Neoplasms; Pravastatin; Risk; Survival Analysis | 1995 |
The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Enzyme Inhibitors; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Scotland | 1995 |
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Death, Sudden, Cardiac; Double-Blind Method; Female; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Tunica Intima; Ultrasonography | 1995 |
Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Carotid Artery Diseases; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin | 1995 |
Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Treatment Outcome | 1995 |
Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris.
Topics: Adult; Aged; Angina, Unstable; Australia; Cholesterol; Double-Blind Method; Female; Humans; Length of Stay; Male; Middle Aged; Myocardial Infarction; Pravastatin; Reference Values; Research Design; Survival Rate | 1995 |
[Life style changes in patients with myocardial infarct in the framework of intramural and ambulatory rehabilitation--results of a German pilot study].
Topics: Adult; Aged; Diet; Exercise; Female; Humans; Life Style; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Pilot Projects; Pravastatin; Quality of Life; Social Support; Stress, Physiological | 1995 |
Pravastatin, lipids, and major coronary events.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Life Tables; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Survival Analysis; Triglycerides | 1994 |
Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hypercholesterolemia; Hypertension; Life Tables; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors; Smoking; Treatment Outcome | 1993 |
Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group.
Topics: Adverse Drug Reaction Reporting Systems; Coronary Disease; Double-Blind Method; Enzyme Inhibitors; Follow-Up Studies; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Record Linkage; Medical Records Systems, Computerized; Middle Aged; Mortality; Myocardial Infarction; Neoplasms; Pravastatin; Prospective Studies; Risk Factors; Scotland | 1995 |
Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dL: baseline results from the Cholesterol and Recurrent Events (CARE) Study.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Coronary Disease; Cross-Sectional Studies; Female; Humans; Intracranial Arteriosclerosis; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peripheral Vascular Diseases; Pravastatin; Prevalence; Recurrence; Risk Factors; Smoking | 1996 |
[Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Cost-Benefit Analysis; Germany; Humans; Hypercholesterolemia; Male; Myocardial Infarction; Pravastatin; Scotland | 1996 |
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Survival Analysis; Treatment Outcome | 1996 |
Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Probability; Risk Factors; Scotland; Time Factors; Treatment Outcome | 1997 |
Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Double-Blind Method; Humans; Lipids; Myocardial Infarction; Pravastatin; Time Factors | 1997 |
[Cholesterol lowering therapy after myocardial infarction. Consequences of the CARE study].
Topics: Adult; Aftercare; Aged; Anticholesteremic Agents; Cause of Death; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Norway; Pravastatin; Recurrence | 1997 |
Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease.
Topics: Absenteeism; Angina, Unstable; Anticholesteremic Agents; Australia; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Health Resources; Humans; Myocardial Infarction; New Zealand; Pravastatin; Quality-Adjusted Life Years; Recurrence; Research Design; Survival Analysis | 1997 |
Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Patient Dropouts; Pravastatin | 1997 |
The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Scotland; Sensitivity and Specificity; Treatment Outcome | 1997 |
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Female; Follow-Up Studies; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Recurrence; Risk Factors; Triglycerides | 1998 |
Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Arteriosclerosis; Carotid Artery, Common; Carotid Stenosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; New Zealand; Pravastatin; Risk Factors; Treatment Outcome; Triglycerides; Ultrasonography | 1998 |
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Artery Bypass; Double-Blind Method; Female; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Myocardial Infarction; Postmenopause; Pravastatin; Recurrence; Survival Rate | 1998 |
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
Topics: Aged; Apolipoproteins; Arteriosclerosis; C-Reactive Protein; Cholesterol; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocarditis; Pravastatin; Protein Precursors; Recurrence; Risk Factors; Serum Amyloid A Protein | 1998 |
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Female; Humans; Incidence; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pravastatin; Risk | 1998 |
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Humans; Male; Myocardial Infarction; Pravastatin; Recurrence; Statistics as Topic | 1998 |
Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Diabetes Complications; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk | 1998 |
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
Topics: Aged; Animals; Anticholesteremic Agents; Cats; Cerebrovascular Disorders; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors; Treatment Outcome; Triglycerides | 1999 |
Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cohort Studies; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Survival Rate; Treatment Outcome; Triglycerides | 1999 |
Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.
Topics: Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Secondary Prevention; Survival Analysis; Treatment Outcome | 1999 |
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.
Topics: Adult; Aged; C-Reactive Protein; Double-Blind Method; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Pravastatin | 1999 |
[Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Prospective Studies; Treatment Outcome | 1999 |
Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Triglycerides; Vasodilation | 2000 |
[Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
Topics: Angina, Unstable; Anticholesteremic Agents; Cost-Benefit Analysis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Pravastatin; Recurrence | 2000 |
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.
Topics: Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Apolipoproteins E; Body Constitution; Body Mass Index; Case-Control Studies; Cholesterol, VLDL; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Triglycerides | 2000 |
Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Chemoprevention; Chi-Square Distribution; Cholesterol, LDL; Cholestyramine Resin; Confidence Intervals; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Drug Combinations; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Niacin; Odds Ratio; Peripheral Vascular Diseases; Pravastatin; Regression Analysis; Statistics, Nonparametric; Stroke; Survival Rate; Treatment Outcome | 2000 |
Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Single-Blind Method; Survival Analysis; Survival Rate; Treatment Outcome; Triglycerides | 2000 |
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Cause of Death; Coronary Disease; Databases, Factual; Double-Blind Method; Doxazosin; Female; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Assessment; Survival Rate; Treatment Outcome; United States | 2001 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Simvastatin; Stroke | 2001 |
Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza n
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Disease-Free Survival; Feeding Behavior; Female; Follow-Up Studies; Humans; Italy; Life Style; Male; Mediterranean Region; Middle Aged; Myocardial Infarction; Pravastatin; Triglycerides | 2000 |
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cholesterol, Dietary; Cohort Studies; Coronary Disease; Double-Blind Method; Doxazosin; Ethnicity; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lisinopril; Male; Middle Aged; Myocardial Infarction; Pravastatin; Racial Groups; Risk Factors; United States | 2001 |
Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cost-Benefit Analysis; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Quality of Life; Secondary Prevention; Sensitivity and Specificity; Survival Rate; United States | 2001 |
The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program.
Topics: Anticholesteremic Agents; Cholesterol; Communication; Female; Humans; Hypertension; Life Style; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Patient Education as Topic; Pravastatin; Risk Factors; Surveys and Questionnaires; Telephone | 2001 |
Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Syndrome | 2001 |
Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial.
Topics: Acute Disease; Angina, Unstable; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Pravastatin; Survival Analysis; Treatment Outcome | 2001 |
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction.
Topics: Aged; Alleles; Anticholesteremic Agents; Female; Gene Deletion; Genotype; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptidyl-Dipeptidase A; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pravastatin; Protein Isoforms; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2001 |
Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE)
Topics: Adult; Aged; Algorithms; Cardiovascular Diseases; Cholesterol; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Research Design; Treatment Outcome | 1991 |
119 other study(ies) available for pravastatin and Myocardial Infarction
| Article | Year |
|---|---|
Pravastatin attenuates atherosclerosis after myocardial infarction by inhibiting inflammatory Ly6C
Topics: Animals; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Plaque, Atherosclerotic; Pravastatin | 2020 |
Persistent psychological distress and mortality in patients with stable coronary artery disease.
Topics: Adult; Aged; Angina, Unstable; Australia; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; New Zealand; Odds Ratio; Pravastatin; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Severity of Illness Index; Stress, Psychological; Surveys and Questionnaires; Time Factors | 2017 |
Pravastatin Decreases Infarct Size Induced by Coronary Artery Ischemia/Reperfusion with Elevated eNOS Expression in Rats.
Topics: Animals; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardium; Nitric Oxide Synthase Type III; Pravastatin; Rats; Rats, Sprague-Dawley; Reperfusion Injury; RNA | 2018 |
Pravastatin improves risk factors but not ischaemic tolerance in obese rats.
Topics: Animals; Blood Glucose; Body Weight; Diet, Carbohydrate Loading; Diet, High-Fat; Disease Models, Animal; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Insulin Resistance; Lipid Peroxidation; Male; Mitochondria; Mitochondrial Dynamics; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Obesity; Pravastatin; Rats; Rats, Wistar; Risk Factors | 2018 |
Cardiovascular disease: The price of a QALY--cost-effectiveness of statins in CKD.
Topics: Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Myocardial Infarction; Pravastatin; Rhabdomyolysis; Stroke | 2013 |
Cardiac troponins: a tool for a personalized medicine strategy in stable coronary artery disease?
Topics: Angina, Unstable; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Troponin I | 2014 |
Do statins have a specific drug effect beyond low-density lipoprotein-cholesterol-lowering in the secondary prevention of coronary artery disease?
Topics: Atorvastatin; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Male; Myocardial Infarction; Pravastatin | 2015 |
Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.
Topics: Adenosine Triphosphatases; Animals; Atorvastatin; Blood Glucose; Cardiotonic Agents; Catalase; Cholesterol; Fatty Acids, Monounsaturated; Fluvastatin; Glutathione; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoproterenol; Male; Myocardial Infarction; Myocardium; Necrosis; Pravastatin; Rats, Wistar; Rosuvastatin Calcium; Simvastatin; Superoxide Dismutase; Triglycerides | 2015 |
Bone marrow mononuclear cells enhance anti-inflammatory effects of pravastatin against isoproterenol-induced myocardial infarction in rats.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Bone Marrow Cells; Combined Modality Therapy; Cytokines; Humans; Isoproterenol; Lipid Peroxidation; Male; Models, Animal; Monocytes; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Oxidative Stress; Pravastatin; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A | 2016 |
Ptosis, diplopia and statins: an association?
Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus | 2008 |
Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Intercellular Adhesion Molecule-1; Male; Myocardial Infarction; Pravastatin; Predictive Value of Tests; Prospective Studies; Risk Factors; Stroke; Time Factors | 2009 |
Rosuvastatin for cardiovascular prevention: too many uncertainties.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; Uncertainty | 2009 |
Mitochondrial K(ATP) channels-derived reactive oxygen species activate pro-survival pathway in pravastatin-induced cardioprotection.
Topics: Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Heart; Humans; In Vitro Techniques; Male; Myocardial Infarction; Myocytes, Cardiac; Potassium Channels; Pravastatin; Protective Agents; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2010 |
Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study.
Topics: Adult; Aged; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Middle Aged; Models, Statistical; Multivariate Analysis; Myocardial Infarction; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2010 |
Effect of pravastatin on ventricular arrhythmias in infarcted rats: role of connexin43.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blotting, Western; Bosentan; Cardiac Pacing, Artificial; Connexin 43; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Fluorescent Antibody Technique; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Maleimides; Mevalonic Acid; Myocardial Infarction; Myocardium; Pravastatin; Protein Kinase C; Protein Kinase Inhibitors; Rats; Rats, Wistar; Receptors, Endothelin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Time Factors; Ultrasonography | 2010 |
The cardio-protective properties of Ncx-6550, a nitric oxide donating pravastatin, in the mouse.
Topics: Animals; Cardiotonic Agents; Heme Oxygenase-1; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Nitrates; Nitric Oxide Donors; Nitrites; Pravastatin; Troponin I | 2010 |
Statins have an early antiplatelet effect in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Arachidonic Acid; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Pravastatin; Simvastatin | 2011 |
HMG CoA reduction in patients with average cholesterol concentrations.
Topics: Cholesterol; Coronary Artery Disease; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence | 2011 |
Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress.
Topics: Animals; Anticholesteremic Agents; Disease Models, Animal; Hypercholesterolemia; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Rabbits; Simvastatin | 2012 |
Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Chi-Square Distribution; Comorbidity; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Polypharmacy; Pravastatin; Propensity Score; Proportional Hazards Models; Pyrroles; Registries; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin; Time Factors; Treatment Outcome | 2014 |
Decreased mortality associated with statin treatment in patients with acute myocardial infarction and lymphotoxin-alpha C804A polymorphism.
Topics: Acute Disease; Aged; Alleles; Animals; Cell Adhesion; Cell Movement; Endoplasmic Reticulum; Female; Follow-Up Studies; Heterozygote; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphotoxin-alpha; Male; Middle Aged; Myocardial Infarction; Myocytes, Cardiac; Polymorphism, Single Nucleotide; Pravastatin; Proportional Hazards Models; Rats; Vascular Cell Adhesion Molecule-1 | 2013 |
Reducing the risk for stroke in patients with myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Topics: Cholesterol; Clinical Trials as Topic; Cohort Studies; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Meta-Analysis as Topic; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Prospective Studies; Risk Assessment; Risk Factors; Scandinavian and Nordic Countries; Stroke; Survival Rate; Time; United States | 2002 |
Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Health Services for the Aged; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; New York; Peripheral Vascular Diseases; Pravastatin; Prospective Studies; Simvastatin; Treatment Outcome; Triglycerides | 2002 |
[Even in advanced age: statins prevent infarct].
Topics: Age Factors; Aged; Cerebral Infarction; Female; Humans; Male; Myocardial Infarction; Pravastatin; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate | 2002 |
[Statins for all seniors?].
Topics: Age Factors; Aged; Cerebral Infarction; Female; Humans; Male; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Survival Rate | 2002 |
LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
Topics: Apolipoprotein C-III; Apolipoproteins C; Case-Control Studies; Cholesterol; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prospective Studies; Recurrence; Risk; Risk Factors; Triglycerides | 2003 |
[Fewer myocardial infarcts. Statin therapy is even effective in the elderly].
Topics: Age Factors; Aged; Anticholesteremic Agents; Cause of Death; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Risk; Secondary Prevention; Survival Rate | 2003 |
[Cardiac rehabilitation in a HIV-patient treated with protease inhibitors].
Topics: Adult; Aspirin; Carbazoles; Carvedilol; Cholesterol; Coronary Angiography; Diet Therapy; Drug Therapy, Combination; Enalapril; Exercise Therapy; HIV Infections; Humans; Male; Myocardial Infarction; Nitrates; Pravastatin; Propanolamines; Protease Inhibitors; Treatment Outcome; Triglycerides | 2003 |
Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction.
Topics: Animals; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Cell Size; Cholesterol; Endothelin-1; Heart Ventricles; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lipids; Male; Myocardial Infarction; Myocytes, Cardiac; Pravastatin; Rats; Rats, Wistar; RNA, Messenger; Up-Regulation; Ventricular Remodeling | 2003 |
Pravastatin reduces the incidence of cardiac events among patients with myocardial infarction.
Topics: Aged; Anticholesteremic Agents; Female; Follow-Up Studies; Guideline Adherence; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Retrospective Studies; Secondary Prevention | 2003 |
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Intensive statin therapy--a sea change in cardiovascular prevention.
Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Lipitor bests Pravachol at certain doses.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention | 2004 |
Cholesterol: low is good. Lower is better. PROVE IT has doctors rethinking how to treat high cholesterol and what's a good target.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values | 2004 |
"Major surprise" in a new study means likely changes in treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values | 2004 |
[Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Risk; Survival Analysis; Survival Rate | 2004 |
New LDL goals: even lower?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Secondary Prevention | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Dropouts; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Triglycerides | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Updated guidelines support even lower cholesterol levels for at-risk patients.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Factors; Risk Reduction Behavior; Simvastatin; Triglycerides; United States | 2004 |
Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3beta and transcription factor beta-catenin.
Topics: Animals; Apoptosis; beta Catenin; Caspase 3; Caspases; Cell Hypoxia; Cell Line; Cytoskeletal Proteins; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Lovastatin; Male; Myocardial Infarction; Myocytes, Cardiac; Pravastatin; Rats; Rats, Wistar; Trans-Activators; Ventricular Remodeling | 2004 |
[Statin therapy in patients with acute coronary syndrome. "Prove-it" study].
Topics: Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Syndrome; Treatment Outcome | 2004 |
Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; Androstadienes; Animals; Cardiotonic Agents; Chromones; Coronary Disease; Dogs; Dose-Response Relationship, Drug; Enzyme Activation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Morpholines; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pravastatin; Pyridines; Quinolines; Signal Transduction; Theophylline; Wortmannin | 2004 |
[Patient feels completely well. The PROCAM Score first reveals the high infarct risk].
Topics: Anticholesteremic Agents; Attitude to Health; Clinical Trials as Topic; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Patient Acceptance of Health Care; Pravastatin; Risk; Risk Factors | 2004 |
How low should your cholesterol go? Even lower may be better. For those at highest risk, very low cholesterol levels may help prevent a second heart attack or stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
What did PROVE-IT prove?
Topics: Anticholesteremic Agents; Atorvastatin; Diabetic Angiopathies; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results; Thrombolytic Therapy | 2004 |
Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
Topics: Adolescent; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hyperlipidemias; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome | 2005 |
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis | 2005 |
[Effects of pravastatin, fosinopril and their combination on myocardium TNF-alpha expression and ventricular remodeling after myocardial infarction in rats].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Drug Therapy, Combination; Fosinopril; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardial Infarction; Pravastatin; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2005 |
Statin use after acute myocardial infarction: a nationwide study in Denmark.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Atorvastatin; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Population Surveillance; Pravastatin; Pyrroles; Registries; Sex Distribution; Simvastatin | 2005 |
Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Drug Utilization; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Thrombolytic Therapy | 2005 |
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome | 2005 |
Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Topics: Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Infections; Male; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
Topics: Age Factors; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Drug Prescriptions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Myocardial Infarction; Odds Ratio; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin-1; Gene Expression Regulation; Heart Ventricles; Hemodynamics; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Imidazoles; Male; Myocardial Infarction; Pravastatin; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Ventricular Remodeling | 2006 |
Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinflammatory mechanism rather than by the induction of angiogenesis.
Topics: Angiogenesis Inducing Agents; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bone Marrow Cells; Bone Marrow Transplantation; Cell Differentiation; Cells, Cultured; Collagen; Combined Modality Therapy; Drug Evaluation, Preclinical; Endothelium, Vascular; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections; Interleukin-1beta; Male; Myocardial Infarction; Neovascularization, Physiologic; Pravastatin; Random Allocation; Rats; Rats, Zucker; Single-Blind Method; Triglycerides; Ultrasonography; Vascular Endothelial Growth Factor A; Ventricular Remodeling | 2006 |
Invited commentary.
Topics: Angiogenesis Inducing Agents; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Marrow Transplantation; Cell Differentiation; Cells, Cultured; Combined Modality Therapy; Drug Evaluation, Preclinical; Endothelium, Vascular; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Models, Animal; Myocardial Infarction; Neovascularization, Physiologic; Pravastatin; Rats; Rats, Zucker; Species Specificity; Vascular Endothelial Growth Factor A | 2006 |
Management of cardiovascular risk in patients receiving calcineurin inhibitors--a case report.
Topics: Acenocoumarol; Amiodarone; Angioplasty; Calcineurin Inhibitors; Carbazoles; Carvedilol; Cyclosporine; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Immunosuppressive Agents; Indoles; Kidney Transplantation; Male; Middle Aged; Myocardial Infarction; Nitroglycerin; Postoperative Complications; Pravastatin; Prednisone; Propanolamines; Risk Factors; Tacrolimus; Treatment Outcome | 2006 |
Pleiotropic effects of statins and early benefit in the PROVE IT-TIMI-22 study.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Endpoint Determination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results | 2006 |
Pravastatin prevents myocardium from ischemia-induced fibrosis by protecting vascular endothelial cells exposed to oxidative stress.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Caspase 3; Cell Line; Endothelial Cells; Endothelium, Vascular; Fibrosis; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Contraction; Myocardial Infarction; Myocardium; Nitric Oxide Synthase Type III; Oxidative Stress; Pravastatin; Rats; Rats, Wistar | 2006 |
Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.
Topics: Aged; Analysis of Variance; Angina Pectoris; C-Reactive Protein; Case-Control Studies; Cholesterol; Enzyme Activation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Pravastatin; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Ventricular Dysfunction, Left; Ventricular Remodeling | 2007 |
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS.
Topics: Alleles; Anticholesteremic Agents; Antigens, CD; Asparagine; Aspartic Acid; Coronary Disease; Genetic Predisposition to Disease; Genotype; Humans; Male; Myocardial Infarction; Odds Ratio; Polymorphism, Single Nucleotide; Pravastatin; Receptors, Fc; Risk Factors; Scotland | 2006 |
Effects of pravastatin on ventricular remodeling by activation of myocardial KATP channels in infarcted rats: role of 70-kDa S6 kinase.
Topics: Animals; Anticholesteremic Agents; Blotting, Western; Electrophysiology; Glyburide; Heart; Immunohistochemistry; Male; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Polymerase Chain Reaction; Potassium Channels; Pravastatin; Rats; Rats, Wistar; Ribosomal Protein S6 Kinases, 70-kDa; Ventricular Remodeling | 2007 |
Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
Topics: Aged; Antihypertensive Agents; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Peptidyl-Dipeptidase A; Pharmacogenetics; Polymorphism, Genetic; Pravastatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment | 2007 |
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
Topics: Aged; Atorvastatin; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Substance Withdrawal Syndrome; Troponin T; Vascular Surgical Procedures | 2007 |
Effect of pravastatin on sympathetic reinnervation in postinfarcted rats.
Topics: Animals; Blotting, Western; Cardiac Pacing, Artificial; Coronary Vessels; Disease Models, Animal; GAP-43 Protein; Glyburide; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; KATP Channels; Ligation; Male; Myocardial Infarction; Myocardium; Neurofilament Proteins; Nicorandil; Norepinephrine; Pinacidil; Polymerase Chain Reaction; Potassium Channel Blockers; Pravastatin; Rats; Rats, Wistar; RNA, Messenger; Sympathetic Nervous System; Tachycardia, Ventricular; Time Factors; Tyrosine 3-Monooxygenase; Ventricular Fibrillation; Ventricular Remodeling | 2007 |
Pravastatin reduces myocardial infarct size via increasing protein kinase C-dependent nitric oxide, decreasing oxyradicals and opening the mitochondrial adenosine triphosphate-sensitive potassium channels in rabbits.
Topics: Animals; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Preconditioning, Myocardial; KATP Channels; Male; Mitochondria, Heart; Myocardial Infarction; Nitric Oxide; Pravastatin; Protein Kinase C; Rabbits; Reactive Oxygen Species; Superoxides | 2007 |
Statin reverses reduction of adiponectin receptor expression in infarcted heart and in TNF-alpha-treated cardiomyocytes in association with improved glucose uptake.
Topics: Acetylcysteine; Adiponectin; Administration, Oral; Animals; Animals, Newborn; Antioxidants; Blood Glucose; Cells, Cultured; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Acids; Glucose; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Ligation; Lipids; Male; Mice; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; Pravastatin; Rats; Rats, Sprague-Dawley; Receptors, Adiponectin; Recombinant Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Time Factors; Tumor Necrosis Factor-alpha | 2007 |
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.
Topics: Anticholesteremic Agents; Case-Control Studies; Coronary Disease; Female; Gene Frequency; Genotype; Humans; Kinesins; Logistic Models; Male; Middle Aged; Myocardial Infarction; Polymorphism, Genetic; Pravastatin; Proportional Hazards Models; Prospective Studies; Risk Factors; Treatment Outcome | 2008 |
The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Case-Control Studies; Coronary Angiography; Female; Humans; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Pravastatin; Prognosis; Risk Factors; Tissue Inhibitor of Metalloproteinase-1 | 2008 |
Does cholesterol depletion have adverse effects on blood rheology?
Topics: Angina, Unstable; Blood Viscosity; Cholesterol; Erythrocyte Deformability; Erythrocytes; Female; Hematocrit; Hemorheology; Humans; Male; Microscopy, Electron, Scanning; Middle Aged; Myocardial Infarction; Pravastatin | 1994 |
Elevated lipoprotein(a) is lowered by a cholesterol synthesis inhibitor in a normocholesterolaemic patient with premature myocardial infarction.
Topics: Adult; Angiography; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Humans; Lipoprotein(a); Male; Myocardial Infarction; Pravastatin; Receptors, LDL; Up-Regulation | 1993 |
[Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Artery Disease; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 1996 |
Clinical significance of pravastatin study results.
Topics: Coronary Disease; Humans; Male; Myocardial Infarction; Pravastatin | 1996 |
Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Artery Diseases; Chemoprevention; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Support Techniques; Hospitalization; Humans; Life Expectancy; Life Tables; Male; Markov Chains; Middle Aged; Myocardial Infarction; Placebos; Pravastatin; Risk Factors; Treatment Outcome; Value of Life | 1996 |
Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Disease; Death, Sudden, Cardiac; Humans; Lovastatin; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence; Scandinavian and Nordic Countries; Simvastatin; Survival Analysis | 1996 |
Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
Topics: Cholesterol; Controlled Clinical Trials as Topic; Humans; Myocardial Infarction; Pravastatin; Recurrence; Survival Rate | 1996 |
Lipid lowering in post-MI patients with normal cholesterol.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence; Reproducibility of Results; Sex Factors; Treatment Outcome | 1997 |
[A break-through in infarct prevention. WOS (West-of-Scotland)-study confirms effectiveness of early intervention using Pravastin].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Humans; Myocardial Infarction; Pravastatin | 1996 |
Lipid-lowering therapy for average lipid levels: the CARE trial.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin | 1997 |
The effect of pravastatin on coronary events after myocardial infarction.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Female; Humans; Myocardial Infarction; Pravastatin; Risk | 1997 |
The effect of pravastatin on coronary events after myocardial infarction.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Myocardial Infarction; Pravastatin; Survival Analysis; Time Factors | 1997 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Humans; Lipids; Lovastatin; Male; Myocardial Infarction; Pravastatin; Simvastatin | 1997 |
Smoking cessation as a rigorous primary intervention for coronary events in middle-aged men. A commentary based on the WOSCOP findings. West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Smoking Cessation | 1997 |
[Care Study. Secondary prevention after myocardial infarct in moderately elevated total cholesterol].
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Combined Modality Therapy; Diet, Fat-Restricted; Humans; Hyperlipidemias; Myocardial Infarction; Pravastatin; Risk Factors; Survival Rate | 1997 |
In search of perverse polymorphisms.
Topics: Anticholesteremic Agents; Blood Coagulation; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Factor VII; Glycoproteins; Humans; Myocardial Infarction; Polymorphism, Genetic; Pravastatin | 1998 |
Aspirin, the poor man's statin?
Topics: Anticoagulants; Aspirin; Female; Humans; Lovastatin; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Risk Factors; Warfarin | 1998 |
[Myocardial protection against cold stress with pravastatin].
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cold Temperature; Heart; Male; Microscopy, Electron; Myocardial Infarction; Myocardium; Pravastatin; Rats; Rats, Wistar; Recurrence; Stress, Physiological | 1998 |
A simple computer program for guiding management of cardiovascular risk factors and prescribing.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Coronary Disease; Female; Humans; Male; Myocardial Infarction; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pravastatin; Risk Assessment; Risk Factors; Smoking; Software | 1999 |
Natural statins and stroke risk.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Humans; Myocardial Infarction; Pravastatin; Simvastatin | 1999 |
Pravastatin shown to reduce stroke risk after heart attacks.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Humans; Myocardial Infarction; Pravastatin | 1999 |
Pravastatin and coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin | 1999 |
[What is the role of pravastatin in the secondary prevention of coronary disease?].
Topics: Adult; Aged; Angina, Unstable; Coronary Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence | 1999 |
The therapeutic gap--compliance with medication and guidelines.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Evidence-Based Medicine; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Compliance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pravastatin | 1999 |
Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction.
Topics: 5'-Nucleotidase; Animals; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Heart Ventricles; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Pravastatin; Rabbits; Treatment Outcome; Triglycerides | 1999 |
[Coronary heart disease: grave deficiencies in secondary prevention. Almost no one is concerned with blood lipids].
Topics: Aged; Anticholesteremic Agents; Combined Modality Therapy; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Simvastatin; Survival Rate | 2000 |
Secondary prevention of hypercholesterolaemia: results of an audit conducted in South Wales.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Medical Audit; Myocardial Infarction; Pravastatin; Treatment Outcome | 2000 |
Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation.
Topics: C-Reactive Protein; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic | 2000 |
Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response.
Topics: Blood Coagulation Factors; Blood Glucose; Case-Control Studies; Cholesterol; Coronary Artery Disease; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors | 2000 |
[Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
Topics: Angina, Unstable; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Middle Aged; Myocardial Infarction; Pravastatin; Quality of Life | 2000 |
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol; Coronary Disease; Fibrinogen; Humans; Hypercholesterolemia; Inflammation; Leukocyte Count; Logistic Models; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Risk Factors; Triglycerides | 2000 |
Pravastatin therapy and the risk of stroke.
Topics: Angina, Unstable; Anticholesteremic Agents; Humans; Myocardial Infarction; Pravastatin; Risk Factors; Stroke | 2000 |
Pravastatin therapy and the risk of stroke.
Topics: Angina, Unstable; Anticholesteremic Agents; Humans; Myocardial Infarction; Pravastatin; Risk Factors; Stroke | 2000 |
Use of the statins in patients after acute myocardial infarction: does evidence change practice?
Topics: Aged; Clinical Trials as Topic; Drug Utilization; Evidence-Based Medicine; Female; Humans; Hypolipidemic Agents; Lipids; Male; Medicine; Myocardial Infarction; Practice Patterns, Physicians'; Pravastatin; Publishing; Simvastatin; Specialization; Survival Rate | 2001 |
[Acute coronary syndrome. Statins in the early phase save lives].
Topics: Angioplasty, Balloon, Coronary; Humans; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Survival Rate | 2001 |
Pravastatin and coronary heart disease.
Topics: Angina, Unstable; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin | 2001 |
[Acute coronary syndrome. Early lipid reduction decreases risk of recurrence].
Topics: Angina, Unstable; Cholesterol, LDL; Humans; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence | 2001 |
[CSE inhibitors after coronary event. How soon administered?].
Topics: Angina, Unstable; Anticholesteremic Agents; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Humans; Myocardial Infarction; Pravastatin | 2001 |
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Pravastatin; Treatment Outcome | 1999 |
Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong.
Topics: Adult; Aged; Clinical Protocols; Cohort Studies; Cost-Benefit Analysis; Female; Health Care Costs; Hong Kong; Humans; Hypercholesterolemia; Long-Term Care; Male; Middle Aged; Myocardial Infarction; Pravastatin; Quality of Life; Secondary Prevention; Sensitivity and Specificity | 2001 |
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endpoint Determination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Risk Factors; Time; Treatment Outcome; Triglycerides | 2002 |
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
Topics: Angina, Unstable; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Chlamydophila Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Myocardial Infarction; Pneumonia, Bacterial; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2002 |
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
Topics: Acute Disease; Cholesterol; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Pravastatin; Proportional Hazards Models; Risk Factors; Simvastatin; Substance Withdrawal Syndrome; Survival Rate; Treatment Outcome; Troponin; United States | 2002 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2002 |